Cathy Eng, VICC Associate Director, Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer, shared a post on X:
“This is the perfect way to end ESMO25!
Celebrating with my workson Van Morris oral presentation!
Also our National Cancer Institute phase 2 ETCTN Nivo/Ipi has just been accepted by Journal of Clinical Oncology.”
More posts about ESMO25 on OncoDaily.
.